Product Code: GMDHC9048IDB
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H1 2017, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.
Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 2, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Atrial Fibrillation - Overview
- Atrial Fibrillation - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Atrial Fibrillation - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Atrial Fibrillation - Companies Involved in Therapeutics Development
- Acesion Pharma Aps
- Allosteros Therapeutics Inc
- ARCA biopharma Inc
- Armetheon Inc
- AstraZeneca Plc
- Bristol-Myers Squibb Company
- Cardiome Pharma Corp
- Daiichi Sankyo Company Ltd
- Dong-A Socio Holdings Co Ltd
- Gilead Sciences Inc
- InCarda Therapeutics Inc
- Merck & Co Inc
- Nissan Chemical Industries Ltd
- Nyken BV
- OMEICOS Therapeutics GmbH
- Verseon Corp
- Atrial Fibrillation - Drug Profiles
- AFC-1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BMS-919373 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- bucindolol hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- budiodarone - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- edoxaban tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- flecainide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy for Atrial Fibrillation - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GS-967 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MK-1832 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NIP-151 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NYK-1112 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- OMT-28 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule for Atrial Fibrillation - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- STP-023725 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vernakalant hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Atrial Fibrillation - Dormant Projects
- Atrial Fibrillation - Discontinued Products
- Atrial Fibrillation - Product Development Milestones
- Featured News & Press Releases
- Feb 23, 2017: Daiichi Sankyo Europe Receives CHMP Positive Opinion for Roteas (edoxaban)
- Feb 13, 2017: Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral anti-arrhythmic budiodarone
- Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
- Nov 09, 2016: Once-Daily Anticoagulant LIXIANA (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism
- Nov 07, 2016: Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016
- Oct 03, 2016: Daiichi Sankyo Announces Large-Scale Registry of Nonvalvular Atrial Fibrillation in the Elderly
- Aug 30, 2016: ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion
- Aug 30, 2016: Trial results for anticoagulants for cardioversion in AF patients published
- Aug 24, 2016: Daiichi Sankyo Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban
- Aug 24, 2016: Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016
- May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study
- May 02, 2016: New drug more effective in treating atrial fibrillation
- Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation
- Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session
- Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development for Atrial Fibrillation, H1 2017
- Number of Products under Development by Companies, H1 2017
- Number of Products under Development by Universities/Institutes, H1 2017
- Products under Development by Companies, H1 2017
- Products under Development by Companies, H1 2017 (Contd..1), H1 2017
- Products under Development by Universities/Institutes, H1 2017
- Number of Products by Stage and Target, H1 2017
- Number of Products by Stage and Mechanism of Action, H1 2017
- Number of Products by Stage and Route of Administration, H1 2017
- Number of Products by Stage and Molecule Type, H1 2017
- Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H1 2017
- Atrial Fibrillation - Pipeline by Allosteros Therapeutics Inc, H1 2017
- Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H1 2017
- Atrial Fibrillation - Pipeline by Armetheon Inc, H1 2017
- Atrial Fibrillation - Pipeline by AstraZeneca Plc, H1 2017
- Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H1 2017
- Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H1 2017
- Atrial Fibrillation - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
- Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
- Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H1 2017
- Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H1 2017
- Atrial Fibrillation - Pipeline by Merck & Co Inc, H1 2017
- Atrial Fibrillation - Pipeline by Nissan Chemical Industries Ltd, H1 2017
- Atrial Fibrillation - Pipeline by Nyken BV, H1 2017
- Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H1 2017
- Atrial Fibrillation - Pipeline by Verseon Corp, H1 2017
- Atrial Fibrillation - Dormant Projects, H1 2017
- Atrial Fibrillation - Dormant Projects, H1 2017 (Contd..1), H1 2017
- Atrial Fibrillation - Dormant Projects, H1 2017 (Contd..2), H1 2017
- Atrial Fibrillation - Discontinued Products, H1 2017
- Atrial Fibrillation - Discontinued Products, H1 2017 (Contd..1), H1 2017
List of Figures
- Number of Products under Development for Atrial Fibrillation, H1 2017
- Number of Products under Development by Companies, H1 2017
- Number of Products under Development by Universities/Institutes, H1 2017
- Number of Products by Top 10 Targets, H1 2017
- Number of Products by Stage and Top 10 Targets, H1 2017
- Number of Products by Top 10 Mechanism of Actions, H1 2017
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
- Number of Products by Routes of Administration, H1 2017
- Number of Products by Stage and Routes of Administration, H1 2017
- Number of Products by Molecule Types, H1 2017
- Number of Products by Stage and Molecule Types, H1 2017
